Thyrocare Technologies Analysis

dividend

Pros

• Dividends after 3 years are expected to be well covered by earnings (2x coverage).

Cons

• Unable to calculate sustainability of dividends as Thyrocare Technologies has not reported any payouts.
• Unable to evaluate Thyrocare Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Thyrocare Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

future

Pros

• Thyrocare Technologies's earnings growth is expected to exceed the India market average.
• Thyrocare Technologies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
• Thyrocare Technologies is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
• Performance (ROE) is expected to be above the current IN Healthcare industry average.
• An improvement in Thyrocare Technologies's performance (ROE) is expected over the next 3 years.
• Thyrocare Technologies's revenue growth is expected to exceed the India market average.

Cons

• Cash flow for Thyrocare Technologies is expected to decrease over the next 2 years.
• Thyrocare Technologies's earnings are expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).
• Thyrocare Technologies's earnings are expected to decrease over the next year.
• Thyrocare Technologies's net income is expected to increase but not above the 50% threshold in 2 years time.
• Thyrocare Technologies's revenue is expected to increase but not above the 50% threshold in 2 years time.
• Thyrocare Technologies's revenue is expected to grow by 8.3% yearly, however this is not considered high growth (20% yearly).

health

Pros

• Thyrocare Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Thyrocare Technologies is profitable, therefore cash runway is not a concern.
• Thyrocare Technologies is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (6705.2%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 60.9x debt.
• Thyrocare Technologies's cash and other short term assets cover its long term commitments.
• Interest payments on debt are well covered by earnings (EBIT is 76x coverage).
• Thyrocare Technologies's level of debt (0.7%) compared to net worth is satisfactory (less than 40%).

Cons

• High level of physical assets or inventory.

management

Pros

• The tenure for the Thyrocare Technologies board of directors is about average.
• Velumani's remuneration is lower than average for companies of similar size in India.
• Velumani's compensation has been consistent with company performance over the past year, both up more than 20%.

Cons

past

Pros

• Thyrocare Technologies's year on year earnings growth rate has been positive over the past 5 years.
• Thyrocare Technologies used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
• Thyrocare Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Thyrocare Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).

Cons

• Thyrocare Technologies's 1-year earnings growth is less than its 5-year average (3.8% vs 14.7%)
• Thyrocare Technologies's earnings growth has not exceeded the IN Healthcare industry average in the past year (3.8% vs 14.4%).

value

Pros

• THYROCARE outperformed the Healthcare industry which returned 8.5% over the past year.
• THYROCARE outperformed the Market in India which returned -14.8% over the past year.

Cons

• Thyrocare Technologies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Thyrocare Technologies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• Thyrocare Technologies is overvalued based on assets compared to the IN Healthcare industry average.
• Thyrocare Technologies is poor value based on expected growth next year.
• Thyrocare Technologies is overvalued based on earnings compared to the IN Healthcare industry average.
• Thyrocare Technologies is overvalued based on earnings compared to the India market.
• NSEI:THYROCARE is flat (0.5%) underperforming the Healthcare industry which returned 5.1% over the past month.
• NSEI:THYROCARE is flat (0.5%) underperforming the market in India which returned 9% over the past month.